Belarus vs Syria: Average cost of drugs for extensively drug-resistant tuberculosis
Belarus
4,600 constant 2022 US$
in 2023
Syria
5,125 constant 2022 US$
in 2023
Belarus rank
13th
Syria rank
10th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Belarus
- Syria
How they compare
Syria currently reports 5,125 constant 2022 US$ against 4,600 constant 2022 US$ in Belarus, a difference of 525 constant 2022 US$.
That makes Syria's figure about 1.1 times Belarus's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Belarus ahead.
Belarus ranks 13th and Syria ranks 10th of 56 countries.
Across the 2 decades both report, Belarus averaged higher in 1 and Syria in 1.
Head to head by decade
| Decade | Belarus | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,617 constant 2022 US$ | 6,000 constant 2022 US$ | 1,617 constant 2022 US$ | Belarus |
| 2020s | 5,867 constant 2022 US$ | 6,042 constant 2022 US$ | 175 constant 2022 US$ | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Belarus or Syria?
- Syria, at 5,125 constant 2022 US$ against 4,600 constant 2022 US$ in Belarus as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Belarus and Syria?
- 525 constant 2022 US$, with Syria ahead.
- How many years of comparable data are there for Belarus and Syria?
- 6 years are reported by both, from 2017 to 2023.
- How do Belarus and Syria rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Belarus ranks 13th and Syria ranks 10th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.